Search

Background: Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by abnormal autoantibody production, inflammation, and organ damage. Most SLE treatment strategies aim to induce remission or reduce disease activity while avoiding flares. Baricitinib has been used effectively to manage various inflammatory diseases, and some randomized controlled trials (RCT) have shown that it is beneficial in treating SLE. The current study aims to assess the efficacy of baricitinib in treating SLE patients. Materials and Methods: Various databases such as PubMed, Scopus, and Science Direct were searched to obtain eligible studies for the present meta‐analysis. Data such as baseline characteristics of patients, doses of the baricitinib, follow‐up duration, and treatment outcome in the form of SLE responder index‐4 (SRI‐4) and lupus low disease activity state (LLDAS) were extracted. Combined odds ratio, 95% confidence interval, and probability values were calculated to study the efficacy of baricitinib in treating SLE patients. A p‐value less than.05 was taken as significant. Comprehensive meta‐analysis v3 was used for all analyses. Results: Three articles were found eligible for the present meta‐analysis comprising 614 patients with placebo, 614 SLE patients receiving 4 mg, and 621 patients with 2 mg of baricitinib. Meta‐analysis revealed a beneficial effect of 4 mg baricitinib in SLE patients compared to placebo, as measured by an increase in the SRI‐4 (p =.006, OR = 1.370) and LLDAS (p =.083, OR = 1.252) rates. In contrast to the placebo group, however, patients receiving 2 mg of baricitinib exhibited no significant improvement. The trial sequential analysis revealed the need for additional RCTs to determine the role of baricitinib in treating SLE patients. Conclusion: In treating SLE patients, administrating a higher dose of baricitinib (4 mg) may be effective. However, additional RCTs in different populations with larger sample sizes are required to validate our findings. [ABSTRACT FROM AUTHOR]

We present a double-pass bismuth (Bi)-doped fiber amplifier (BDFA) providing high-gain wideband amplification from 1330 to 1480 nm. A peak gain of 38 dB with 4.7 dB noise figure (NF) was obtained at 1420 nm for a -23 dBm input signal, with >20 dB gain from 1335 to 1475 nm. We achieved 30  and 21.5 dB peak gains with 122 nm (1341-1463 nm) and 140 nm (1333-1473 nm) 6 dB-gain bandwidth for -10 and 0 dBm input signal, respectively. For a 0 dBm signal, the power conversion efficiency (PCE) reached 23.7%, and the in-band optical-signal-to-noise ratio (OSNR) across the wideband BDFA was >44 dB. Also, the absorption and luminescence characteristics have been studied for different Bi-doped phosphosilicate fibers (BPSFs) fabricated in-house.

Lasers stabilized to optical fiber delay lines have been shown to deliver a comparable short-term (<1 s) frequency noise performance to that achieved by lasers stabilized to ultra-low expansion (ULE) cavities, once the linear frequency drift has been removed. However, for continuous stable laser operations, the drift can be removed only when it can be predicted, e.g., when it is linear over very long timescales. To date, such long-term behaviour of the frequency drift in fiber delay lines has not been, to the best of our knowledge, characterised. In this work we experimentally characterise the frequency drift of a laser stabilised to a 500 m-long optical fiber delay line over the course of several days. We show that the drift still follows the temperature variations even when the spool temperature is maintained constant with fluctuations below tens of mK. Consequently, the drift is not linear over long timescales, preventing a simple feed-forward compensation. However, here we show that the drift can be reduced by exploiting the high level of correlation between laser frequency and the fiber temperature. In our demonstration, by applying a frequency correction proportional to temperature readings, a calculated frequency drift of less than 16 Hz/s over the several days of our test was obtained, corresponding to a 23-fold improvement from uncorrected values.

We present wavelength-division multiplexed coherent transmission in an O-band amplified link enabled by bismuth-doped fiber amplifiers (BDFAs). Transmission of 4 × 25 GBd DP-16QAM (4 × 200 Gb/s) is demonstrated over a single span of 50-km length, occupying a bandwidth of 4.7 THz across the wavelengths 1323 nm to 1351 nm.